Woman who suffered an assortment of VACCINE INJURIES during clinical trial sues AstraZeneca for BREACH OF CONTRACT

05/22/2024 / By Ava Grace

A trial participant who suffered an assortment of vaccine injuries due to AstraZeneca’s Wuhan coronavirus (COVID-19) injection has sued the Anglo-Swedish pharmaceutical firm for breach of contract.

On May 13, Utah resident and preschool instructor Brianne Dressen took AstraZeneca to court. She alleged that the vaccine maker had breached a contract with her by refusing to pay for the necessary medical care to address her vaccine injury. According to Dressen’s court filings, she has shelled out thousands of dollars for medications to address her neurological issues and other health problems.

Dressen decided to take part in a clinical study run by AstraZeneca and Velocity, the company commissioned to run the trial, in 2020. The portion of the consent form she completed stated that AstraZeneca promised to “pay the costs of medical treatment” and “cover the costs of research injuries.” She affixed her signature to the consent form, spurred on by these assurances. (Related: Australian actress sues AstraZeneca for life-threatening vaccine injury, but continues to ADVOCATE for other covid-19 “vaccines.”)

Dressen soon began to have symptoms – such as nausea, tinnitus, and impaired vision – after being injected. Later on, she had heart rate spikes and developed an extraordinary sensitivity to light. She visited several physicians to obtain a diagnosis and receive therapy. As per documents seen by the Epoch Times, the Utah resident was diagnosed with “post-vaccine neuropathy” by U.S. specialists at the National Institutes of Health in 2021.

The bills for the prescription medications and doctor appointments soon started to mount. Just the immunoglobulin antibodies that government physicians suggested cost $9,909.82 each month. Given this, Dressen and her spouse kept both AstraZeneca and Velocity informed of the mounting expenses.

Family of vaccine-injured trial participant forced to remortgage house to pay for treatments

The Dressen family messaged Velocity on Jan. 15, 2021 with the first set of treatment payment records, but a company official only promised to “reach out again.” They were forced to remortgage their house to pay for treatments.

Two messages in March from Dressen were met with generic replies from Velocity representatives. Months passed throughout the back and forth, with the Utah resident still receiving no payment in return.

It was only in July 2021 that the Dressens received an initial payment of $590.20, which followed a local television station reporting on the case. A Velocity official called the family to inform them of the payment, adding that it was in communication with AstraZeneca about the authorization of supplementary payouts.

The official later provided Dressen a statement to sign in December 2021. In exchange for renouncing any further claims for payment, she would accept $1,243 – double the amount she was initially paid. She and her husband rejected the offer, finding it “offensive.”

AstraZeneca staff began reaching out with the Dressens directly in March 2022, asking for their billing and medical records. A representative later wrote in August 2022 that the drug company was awaiting provider medical records to evaluate the claims. They wrote the following month that all of the medical records had been received – but as per the lawsuit, neither AstraZeneca nor Velocity got in touch with Dressen or her husband again after the September 2022 exchange.

“I did everything they asked of me. I honored my obligations to them. They have not honored any,” Dressen said in a statement. “When they needed me, I was there, I cooperated. When I needed them, they were nowhere to be found.”

The corporations are accused of violating both contract and duty in the lawsuit. It requests damages for prejudgment interest, attorney fees, medical costs, mental distress and lost income. Dressen is requesting a trial by jury.

In the U.S., AstraZeneca’s vaccine was never approved for usage outside of clinical trials. Due to low demand, the company stated earlier this month that it is discontinuing its COVID-19 vaccine. The disclosure was made several months after it was discovered that the injection may result in thrombosis with thrombocytopenia syndrome, a condition marked by low platelet counts and blood clots.

Visit BigPharmaNews.com for more similar stories.

Watch Jefferey Jaxen and Del Bigtree discussing the fallout at AstraZeneca amid the withdrawal of its COVID-19 injection below.

This video is from The Highwire with Del Bigtree channel on Brighteon.com.